National Institutes of Health to Grant Exclusive License for Cystic Fibrosis Treatment to SciClone Pharmaceuticals

Summary

The National Institutes of Health is considering a worldwide, limited field of use, exclusive license to practice certain inventions related to treating cystic fibrosis and other human diseases to SciClone Pharmaceuticals, Inc., in exchange for royalties.